Lotus Eye Hospital And Institute Ltd (LOTUSEYE) AI Stock Analysis

• Market Cap: ₹2.27B
• Dividend Yield: N/A
• Average Volume (3M): 2.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: 3.28%
• EPS Growth: -52.11%
• Country: IN
• Employees: 336
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.13
• Shares Outstanding: 20,796,330
• 10 Day Avg. Volume: 4,541
• 30 Day Avg. Volume: 2,230
• PEG Ratio: -2.60
• Price to Book (P/B): 2.43
• Price to Sales (P/S): 2.94
• P/FCF Ratio: -68.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: ₹116.00 ▼(-1.78% Downside)
• Action: Reiterated Date: 12/13/25
• Date: Action: Reiterated 12/13/25

Lotus Eye Hospital And Institute Ltd's stock score is primarily driven by strong technical momentum and a solid financial foundation. However, the high P/E ratio suggests overvaluation, and declining profit margins pose a risk to future profitability. The absence of earnings call insights and corporate events limits additional context.

Positive Factors

Specialized Ophthalmology Focus

Specialization in ophthalmology builds clinical expertise, standardized procedures and referral networks that sustain demand and operational efficiency. Over a 2–6 month horizon this durable focus supports steady patient volumes, repeatable revenue streams and scalable care pathways.

Consistent Revenue Growth

Steady revenue expansion from 2021 to 2025 indicates rising market penetration and patient volumes. Persistent top-line growth supports better capacity utilization, underpins investment capacity and provides a structural base to absorb short-term cost pressure while pursuing measured expansion.

Robust Balance Sheet / Low Leverage

A strong equity base and low leverage provide durable financial resilience, enabling the company to fund capex, weather demand shocks and pursue strategic initiatives without immediate refinancing. This structural strength improves long-term solvency and optionality.

Negative Factors

Shrinking Gross Margins

Severe gross margin compression over several years signals rising input costs or pricing pressure that erodes fundamental profitability. If persistent, diminished gross margins reduce operating leverage, limit reinvestment capacity and materially weaken long-term return on services.

Negative Free Cash Flow

Sustained negative free cash flow driven by higher capex reduces internal funding for operations and growth. Over months this increases reliance on external financing, risks liquidity strain and can constrain strategic flexibility if revenue improvement doesn't restore positive cash generation.

Concentration / Payer Mix Uncertainty

Heavy concentration in ophthalmology and an unclear payer mix create structural revenue risk. Dependence on patient self-pay and unspecified insurer/government reimbursement exposes margins to reimbursement changes and demand shifts, limiting diversification and increasing regulatory sensitivity.

Lotus Eye Hospital And Institute Ltd Business Overview & Revenue Model

Company Description

Lotus Eye Hospital and Institute Limited, an eye hospital, provides eye care services in India. It offers services in the areas of refractive surgery, retina and uvea, cornea, glaucoma, paediatric and squint, computer vision syndrome, orbit and oculoplasty, neuro ophthalmology, and binocular vision. The company also provides cataract and intraocular lenses, as well as operates an eye bank. In addition, it offers ophthalmic fellowship training courses in cornea, glaucoma, retina, and anterior segments, as well as DNB teaching and training services. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was incorporated in 1997 and is based in Coimbatore, India.

How the Company Makes Money

Lotus Eye Hospital and Institute Ltd primarily generates revenue by delivering paid eye-care services to patients through its facilities. Key revenue streams typically include (1) outpatient services such as consultations, diagnostic tests, refraction and optometry services; (2) surgical and procedural revenue from ophthalmic operations (e.g., cataract and other eye surgeries) and associated operation-theatre/clinical charges; (3) inpatient and day-care charges where applicable, including room/bed charges and bundled procedure packages; and (4) pharmacy, consumables, and optical sales linked to treatments (e.g., lenses, frames, medicines, intraocular lenses and other surgical consumables charged to patients or included in procedure packages). Payments may come directly from patients as self-pay and/or through third-party payors such as insurers or government/TPA reimbursement mechanisms where the company is empaneled; specific payer mix, partnership arrangements, and the contribution of each stream are null.

Lotus Eye Hospital And Institute Ltd Financial Statement Overview

Summary

Lotus Eye Hospital And Institute Ltd shows strong revenue growth and a robust balance sheet with low leverage. However, declining profit margins and negative free cash flow indicate challenges in profitability and liquidity management.

Income Statement

Lotus Eye Hospital And Institute Ltd has shown steady revenue growth, moving from ₹316.67M in 2021 to ₹495.62M in 2025. The Gross Profit Margin has decreased over the years, from 50.56% in 2021 to 20.26% in 2025, indicating increased cost pressures. The Net Profit Margin has also declined, reflecting challenges in maintaining profitability despite revenue growth.

Balance Sheet

The company maintains a strong equity base with Stockholders' Equity at ₹600.00M in 2025. The Debt-to-Equity ratio is low, suggesting prudent leverage management. However, the Equity Ratio has slightly decreased, indicating a marginal increase in liabilities over time. Overall, the balance sheet remains robust, providing a stable financial foundation.

Cash Flow

Operating Cash Flow has seen fluctuations but remained positive, providing a reliable cash flow source. However, Free Cash Flow has turned negative in recent years, driven by increased capital expenditures, indicating potential liquidity concerns if not balanced with future revenue growth.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	503.15M	495.63M	482.10M	470.44M	389.10M	323.59M
Gross Profit	219.82M	100.41M	135.66M	121.38M	192.53M	85.70M
EBITDA	40.71M	47.44M	79.42M	88.37M	68.09M	44.59M
Net Income	6.74M	7.39M	29.14M	40.77M	29.84M	15.68M
Balance Sheet
Total Assets	715.15M	695.74M	666.27M	631.88M	615.97M	592.29M
Cash, Cash Equivalents and Short-Term Investments	32.49M	39.78M	69.30M	83.31M	87.93M	98.92M
Total Debt	47.99M	34.30M	11.10M	11.04M	12.38M	3.99M
Total Liabilities	108.97M	95.73M	72.17M	56.09M	69.88M	65.32M
Stockholders Equity	606.18M	600.00M	594.09M	575.79M	546.09M	526.97M
Cash Flow
Free Cash Flow	-2.68M	-21.25M	403.00K	12.90M	-2.73M	22.55M
Operating Cash Flow	5.09M	27.02M	56.83M	43.87M	44.12M	27.30M
Investing Cash Flow	-4.83M	-43.50M	-46.33M	-21.94M	-39.35M	4.86M
Financing Cash Flow	-9.27M	-12.42M	-34.02M	-17.05M	-15.75M	-3.19M

Lotus Eye Hospital And Institute Ltd Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 118.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LOTUSEYE, the sentiment is Neutral. The current price of 118.1 is above the 20-day moving average (MA) of 108.81, above the 50-day MA of 115.43, and above the 200-day MA of 105.04, indicating a neutral trend. The MACD of -2.83 indicates Negative momentum. The RSI at 46.91 is Neutral, neither overbought nor oversold. The STOCH value of 67.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:LOTUSEYE.

Lotus Eye Hospital And Institute Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	75 Outperform	₹92.68B	63.11	―	0.20%	16.71%	13.92%
HCG	67 Neutral	₹81.07B	-247.47	―	―	17.58%	-38.20%
LOTUSEYE	64 Neutral	₹2.27B	-237.80	―	―	3.28%	-52.11%
KRSNAA	62 Neutral	₹19.01B	38.37	―	0.38%	11.51%	21.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SHALBY	50 Neutral	₹15.12B	310.39	―	0.59%	11.49%	-91.65%

Lotus Eye Hospital And Institute Ltd Corporate Events

Lotus Eye Hospital Fined by BSE, NSE for Governance Non-Compliance

Lotus Eye Hospital and Institute Ltd has disclosed that both BSE and NSE have imposed fines of Rs 2,17,120 each, including GST, for non-compliance with Regulation 17(1A) of SEBI’s Listing Obligations and Disclosure Requirements. The violation relates to corporate governance norms concerning board composition, but the company stated that there is no material impact on its financial or operational performance.

The hospital chain said the non-compliance has already been rectified following shareholder approval via postal ballot on January 17, 2026, and noted that similar fines up to the quarter ended September 30, 2025, have been reviewed by its board and duly paid. The latest penalties pertain to the quarter ended December 31, 2025, underscoring ongoing regulatory scrutiny of the company’s adherence to listing requirements even as it moves to regularize its governance framework.